Stay updated with breaking news from Chugai pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
James Sabry, Roche's global head of partnering, retires after 14 years mmm-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mmm-online.com Daily Mail and Mail on Sunday newspapers.
Week In Review: LianBio To Close Operations; Will Pay $528M To Shareholders seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Week In Review: SystImmune Out-Licenses Global Rights For ADC To BMS In $8.4B Deal seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Antibody-drug conjugates 'the next pillar of cancer therapeutics' healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.Patients with MET-positive status appeared five times as likely as those with MET-negative status to respond to amivantamab (Rybrevant, Janssen) plus lazertinib
CHICAGO — Platinum-doublet chemotherapy did not extend survival for patients with advanced nonsquamous non-small cell lung cancer who responded to EGFR tyrosine kinase inhibitor therapy, according to randomized phase 3 study results.The regimen prolonged PFS but did not confer an OS benefit, findings presented at ASCO Annual Meeting showed.
The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In
CHICAGO — The addition of panitumumab vs. bevacizumab to standard doublet chemotherapy significantly extended survival among patients with RAS wild-type and left-sided metastatic colorectal cancer, according to study results.The panitumumab (Vectibix, Amgen) regimen conferred median OS of more than 3 years —— the longest survival ever reported in a first-line, prospective phase